Ellis Investment Partners’s GSK GSK Stock Holding History

Ellis Investment Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,912	Closed	-$56K	–	415
2022 Q3	$56K	Buy	1,912 +309	+19%	+$11.7K	0.02%	376
2022 Q2	$87K	Buy	1,603 +19	+1%	+$1.05K	0.02%	325
2022 Q1	$86K	Sell	1,584 -75	-5%	-$4.07K	0.02%	341
2021 Q4	$91K	Buy	1,659 +1,078	+186%	+$56.1K	0.02%	337
2021 Q3	$27K	Buy	581 +5	+0.9%	+$251	0.01%	475
2021 Q2	$28K	Buy	576 +6	+1%	+$288	0.01%	469
2021 Q1	$25K	Sell	570 -4	-0.7%	-$182	0.01%	472
2020 Q4	$26K	Buy	574 +13	+2%	+$597	0.01%	453
2020 Q3	$26K	Buy	561 +4	+0.7%	+$200	0.01%	443
2020 Q2	$28K	Buy	557 +6	+1%	+$308	0.01%	425
2020 Q1	$25K	Buy	551 +209	+61%	+$11.1K	0.01%	379
2019 Q4	$20K	Sell	342 -476	-58%	-$26.5K	0.01%	435
2019 Q3	$43K	Buy	818 +484	+145%	+$24.9K	0.02%	358
2019 Q2	$16K	Buy	+334	New	+$16.8K	0.01%	468

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ellis Investment Partners's GSK Position: Q4 2022 in Review

Ellis Investment Partners sold out of GSK (GSK) in Q4 2022, closing a stake of 1,912 shares — an estimated $56K sold.

Ellis Investment Partners first reported a position in GSK in Q2 2019 and held it in 14 quarters. The position peaked at $91K in Q4 2021. 813 funds tracked by Wall St. Rank hold GSK as of Q4 2022.

Ellis Investment Partners reported no remaining GSK position as of Q4 2022 after selling out during the quarter.
Ellis Investment Partners sold 1,912 GSK shares in Q4 2022, an estimated $56K.
Ellis Investment Partners first reported a position in GSK in Q2 2019 and held it in 14 quarters.
Ellis Investment Partners's GSK position peaked at $91K in Q4 2021.
813 funds tracked by Wall St. Rank held GSK as of Q4 2022.

Based on Ellis Investment Partners's 13F filing for Q4 2022, filed 31 Jan 2023.